Agios Pharmaceuticals is progressing with its Phase 3 RISE UP trial for Pyrocaine (mitapivat) in sickle cell disease, with results expected by end of 2025. The study aims to demonstrate a 30% reduction in pain crises and improved hemoglobin levels. Additionally, the company plans to initiate a Phase 2 trial for their second PK activator, TevaPIVID, in sickle cell disease by mid-2025. With $1.5 billion in cash, Agios is building a potential franchise for this high unmet need disease.

At OxyDial, we’re encouraged by Agios’ comprehensive approach to sickle cell disease. Their focus on addressing both hemolytic anemia and vaso-occlusion could provide meaningful benefits for patients suffering from “bone-crushing fatigue” and painful crises. We believe providing multiple treatment options is essential for this complex condition affecting millions worldwide.

Read more: https://www.investing.com/news/transcripts/agios-pharmaceuticals-at-barclays-conference-strategic-advances-in-rare-disease-treatments-93CH-3924683

#SickleCell #RareDiseases #Hematology #AgiosPharmaceuticals #PKActivation #ClinicalTrials #MedicalInnovation #HealthcareNews #Oxydial